Dalia HAMMOUD, Mazen SHAHEEN, Rayane NASSAR

Imatinib (Gleevec) induced worsening of pericardial effusion in CML

Gleevec (imatinib mesylate), Philadelphia kromozomu pozitif kronik fazdaki kronik miyeloid lösemili (KML) erişkin hastanın tedavisinde kullanılmaktadır. Gleevec, sıklıkla ödem ve şiddetli sıvı retansiyonuna neden olur. Gleevec alan ve yeni tanı konulmuş KML’li hastaların %1.3’ünde, erişkin hastaların ise %2-%6’sında sıvı retansiyon reaksiyonu (plevral effüzyon, perikardial effüzyon, pulmoner ödem ve assit gibi) olduğunu bildiren birkaç rapor yayınlanmıştır. Bu çalışmada, Gleevec başlandıktan sonra perikardial effüzyonu artan KML’li hasta rapor edildi.

Kronik miyeloid lösemide ımatinib (Gleevec) ile atış gösteren perikardial effüzyon

Gleevec (imatinib mesylate) is indicated for the treatment of newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) in chronic phase. Gleevec is often associated with edema and occasionally serious fluid retention. Severe fluid retention (e.g., pleural effusion, pericardial effusion, pulmonary edema, and ascites) reactions were reported in 1.3% of newly diagnosed CML patients taking Gleevec, and in 2%-6% of other adult CML patients taking Gleevec. We report a case of a patient with CML and a pericardial effusion worsening after initiating Gleevec.

PDF

___

1. Breccia M, D’elia GM, D’Andrea M, et al. Pleuralpericardic effusion as uncommon complication in CML patients treated with Imatinib. Eur J Haematol 2005; 74: 89-90.
2. Strupp C, Germing U, Trommer I, et al. Pericardial effusion in chronic myelomonocytic leukemia (CMML):a case report and review of the literature. Leuk Res 2000; 24: 1059-1062.
3. Martinoni A, Cipolla CM, Cardinale D, et al. Long Term Results of Intrapericardial Chemotherapeutic Treatment of Malignant Pericardial Effusions with Thiotepa. Chest 2004; 126: 1412-1416.
4. Chiles C, Woodard Pk, Gutierrez FR, et al. Metastatic Involvement of the Heart and Pericardium: CT and MR Imaging. Radiographics 2001; 21: 439-449.